Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Diabetes Drugs to Face Tougher Risk Scrutiny
Diabetes Drugs to Face Tougher Risk Scrutiny
Diabetes Drugs to Face Tougher Risk Scrutiny
Submitted by
admin
on December 18, 2008 - 7:15am
Source:
WSJ Online
News Tags:
diabetes
GSK
Avandia
Eli Lilly
Amylin
Byetta
Bristol-Myers Squibb
AstraZeneca
saxagliptin
Headline:
Diabetes Drugs to Face Tougher Risk Scrutiny
Do Not Allow Advertisers to Use My Personal information
